Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Xilio Therapeutics, Inc. (XLO) had Return on Tangible Equity of -123.97% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$2.93M |
|
$-13.27M |
|
-- |
|
$2.93M |
|
$16.78M |
|
$-13.85M |
|
$0.59M |
|
$-13.27M |
|
$-13.27M |
|
$-13.27M |
|
$-13.27M |
|
$-13.27M |
|
$-13.27M |
|
$-13.85M |
|
$-13.35M |
|
74.70M |
|
74.70M |
|
$-0.18 |
|
$-0.18 |
|
| Balance Sheet Financials | |
$93.20M |
|
$4.29M |
|
$10.52M |
|
$103.72M |
|
$47.64M |
|
-- |
|
$45.38M |
|
$93.02M |
|
$10.70M |
|
$10.70M |
|
$10.70M |
|
51.77M |
|
| Cash Flow Statement Financials | |
$28.98M |
|
$-0.02M |
|
$4.83M |
|
$57.07M |
|
$90.86M |
|
$33.79M |
|
$1.53M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.96 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-472.73% |
|
-472.73% |
|
-- |
|
-452.73% |
|
-452.73% |
|
$28.96M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
-- |
|
-- |
|
-- |
|
-123.97% |
|
|
Return on Tangible Equity |
-123.97% |
-12.79% |
|
-123.97% |
|
$0.21 |
|
$0.39 |
|
$0.39 |
|